Abbott Laboratories (ABT) Net Cash Flow (2009 - 2026)

Abbott Laboratories' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$1.7 billion for Q1 2026.

• In Q1 2026, Net Cash Flow fell 53.07% year-over-year to -$1.7 billion; the TTM figure through Mar 2026 stood at $247.0 million (down 13.03% YoY), while the FY2025 annual figure was $835.0 million, up 2.33% from the prior year.
• Net Cash Flow came in at -$1.7 billion for Q1 2026 at Abbott Laboratories, down from $1.0 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
• A 5-year average of -$164.9 million and a median of $162.0 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 269.71% in 2022 and surged 612.77% in 2025, its largest moves.
• Abbott Laboratories' Net Cash Flow stood at $237.0 million in 2022, then sank by 31.65% to $162.0 million in 2023, then retreated by 12.96% to $141.0 million in 2024, then soared by 612.77% to $1.0 billion in 2025, then tumbled by 268.76% to -$1.7 billion in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.7 billion, $1.0 billion, and $570.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison